Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes.
Hasegawa G, Kajiyama S, Tanaka T, Imai S, Kozai H, Fujinami A, Ohta M, Obayashi H, Park H, Nakano K, Tanaka M, Shiraishi E, Fukui M, Yoshikawa T, Nakamura N. Hasegawa G, et al. Among authors: obayashi h. Clin Chim Acta. 2008 Apr;390(1-2):110-4. doi: 10.1016/j.cca.2008.01.005. Epub 2008 Jan 12. Clin Chim Acta. 2008. PMID: 18230353 Clinical Trial.
Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension.
Park H, Hasegawa G, Obayashi H, Fujinami A, Ohta M, Hara H, Adachi T, Tamaki S, Nakajima Y, Kimura F, Ogata M, Fukui M, Yoshikawa T, Nakamura N. Park H, et al. Among authors: obayashi h. Clin Chim Acta. 2006 Dec;374(1-2):129-34. doi: 10.1016/j.cca.2006.06.004. Epub 2006 Jun 12. Clin Chim Acta. 2006. PMID: 16857181
Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes.
Nakano K, Hasegawa G, Fukui M, Yamasaki M, Ishihara K, Takashima T, Kitagawa Y, Fujinami A, Ohta M, Hara H, Adachi T, Ogata M, Obayashi H, Nakamura N. Nakano K, et al. Among authors: obayashi h. Endocr J. 2010;57(5):423-30. doi: 10.1507/endocrj.k10e-006. Epub 2010 Feb 17. Endocr J. 2010. PMID: 20160397 Free article. Clinical Trial.
Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes.
Ichida Y, Hasegawa G, Fukui M, Obayashi H, Ohta M, Fujinami A, Ohta K, Nakano K, Yoshikawa T, Nakamura N. Ichida Y, et al. Among authors: obayashi h. Pharmacology. 2006;76(1):34-9. doi: 10.1159/000088948. Epub 2005 Oct 14. Pharmacology. 2006. PMID: 16227702 Clinical Trial.
Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats.
Hasegawa G, Fukui M, Hosoda H, Asano M, Harusato I, Tanaka M, Shiraishi E, Senmaru T, Sakabe K, Yamasaki M, Kitawaki J, Fujinami A, Ohta M, Obayashi H, Nakamura N. Hasegawa G, et al. Among authors: obayashi h. Eur J Pharmacol. 2009 Mar 1;605(1-3):164-9. doi: 10.1016/j.ejphar.2009.01.001. Epub 2009 Jan 10. Eur J Pharmacol. 2009. PMID: 19171132
The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels.
Park H, Hasegawa G, Shima T, Fukui M, Nakamura N, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Kitawaki J, Ohta M, Obayashi H, Okanoue T. Park H, et al. Among authors: obayashi h. Clin Chim Acta. 2010 Nov 11;411(21-22):1735-40. doi: 10.1016/j.cca.2010.07.012. Epub 2010 Jul 21. Clin Chim Acta. 2010. PMID: 20654606
177 results